148533-52-2

Upstream product

• 50972-25-3 C₁₃H₁₂ClO₂P 
• 38969-40-3 Ecgonine methyl ester hydrochloride 
• 7143-09-1 methyl ecgonine 
• 824-72-6 P,P-dichlorophenylphosphine oxide 
• 53-21-4 (-)-cocaine hydrochloride 

Downstream Products

• 1431753-56-8 4-((1R,2R,3S,5S)-3-(((benzyloxy)(phenyl)phosphoryl)oxy)-2-(methoxycarbonyl)-8-azabicyclo[3.2.1]octan-8-yl)-4-oxobutanoic acid trifluoroacetate salt 
• 1431753-57-9 4-((1R,2R,3S,5S)-3-((hydroxy(phenyl)phosphoryl)oxy)-2-(methoxycarbonyl)-8-azabicyclo[3.2.1]octan-8-yl)-4-oxobutanoic acid trifluoroacetate salt 
• 148533-53-3 (1R,2R,3S,5S)-3-(Benzyloxy-phenyl-phosphinoyloxy)-8-(5-tert-butoxycarbonyl-pentyl)-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester 
• 148533-51-1 (1R,2R,3S,5S)-methyl 3-(((benzyloxy)(phenyl)phosphoryl)oxy)-8-azabicyclo[3.2.1]octane-2-carboxylate 

Relevant academic research and scientific papers

Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design

Presently, there are no FDA-approved medications to treat cocaine addiction. Active vaccination has emerged as one approach to intervene through the rapid sequestering of the circulating drug, thus terminating both psychoactive effects and drug toxicity. Herein, we report our efforts examining two complementary, but mechanistically distinct active vaccines, i.e., noncatalytic and catalytic, for cocaine treatment. A cocaine-like hapten GNE and a cocaine transition-state analogue GNT were used to generate the active vaccines, respectively. GNE-KLH (keyhole limpet hemocyannin) was found to elicit persistent high-titer, cocaine-specific antibodies and blunt cocaine-induced locomotor behaviors. Catalytic antibodies induced by GNT-KLH were also shown to produce potent titers and suppress locomotor response in mice; however, upon repeated cocaine challenges, the vaccine's protecting effects waned. In depth kinetic analysis suggested that loss of catalytic activity was due to antibody modification by cocaine. The work provides new insights for the development of active vaccines for the treatment of cocaine abuse.

Cocaine catalytic antibodies: The primary importance of linker effects

Current treatments for cocaine addiction are not effective. The development of a catalytic monoclonal antibody (mAb) provides a strategy for not only binding, but also degrading cocaine, which offers a broad-based therapy. Hapten design is the central element for programming antibody catalysis. The characteristics of the linker used in classic transition-state analogue phosphonate haptens were shown to be important for obtaining mAbs that hydrolyze the benzoate ester of cocaine.